Entry Rationale
The current stock price of $26.67 is positioned at the midpoint between the support level of $29.93 and the resistance level of $33.06, indicating a potential opportunity for a short-term rebound.
Progyny Non-GAAP EPS of $0.55 beats by $0.03, revenue of $350.5M beats by $1.85M
Progyny reported that its Non-GAAP EPS for Q2 2026 was $0.55, exceeding market expectations of $0.52, and revenue was $350.5M, surpassing the anticipated $348.65M.
The current stock price of $26.67 is positioned at the midpoint between the support level of $29.93 and the resistance level of $33.06, indicating a potential opportunity for a short-term rebound.
If the stock price clearly breaks through the resistance level of $33.06 and holds, take profits; if it closes below the support level of $29.93, cut losses.
RSI(14) 45.6, moving averages in a positive alignment, trading volume at 0.61 times the 20-day average, recent 7-day volatility -0.7%
Past similar cases such as BLMN, APPS, and EMBC all experienced increases driven by 'Earnings Beat' news, and this time PGNY also has a similar catalyst structure as its Non-GAAP EPS and revenue exceeded expectations.
While it was confirmed that the performance and revenue exceeded expectations, the stock price fell significantly below expectations, reaching the stop-loss level. This suggests a lack of short-term buying pressure and a considerable impact from broader market or sector adjustments.
In the future, we will consider entering positions after confirming an increase in trading volume along with news, and on days with high volatility, we will reduce position sizes to manage volatility risk.